• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

小儿实体器官移植受者巨细胞病毒管理与治疗的辩论:基于病例的讨论

Debates in Management and Treatment of CMV in Pediatric Solid Organ Transplant Recipients: A Case-Based Discussion.

作者信息

Downes Kevin J, Danziger-Isakov Lara, Varela-Fascinetto Gustavo, Herold Betsy C, Green Michael, L'Huillier Arnaud G

机构信息

Department of Pediatrics, Perelman School at Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

出版信息

Pediatr Transplant. 2025 Aug;29(5):e70135. doi: 10.1111/petr.70135.

DOI:10.1111/petr.70135
PMID:40671272
Abstract

The recently published 4th International Consensus Guidelines on the Management of CMV in Solid-Organ Transplantation offers updated recommendations for CMV prevention, treatment, and monitoring in pediatric solid organ transplant (pSOT) recipients. Although these guidelines are supported by a thorough review of published data, there remain unanswered questions due to a paucity of pediatric data, conflicting findings across studies, or areas where pediatric and adult data are divergent. The current report highlights controversial areas of management, emphasizes the rationale for certain expert opinions, and calls attention to topics that require further research using a case-based approach.

摘要

最近发布的《实体器官移植中巨细胞病毒管理的第4版国际共识指南》为小儿实体器官移植(pSOT)受者的巨细胞病毒预防、治疗和监测提供了更新的建议。尽管这些指南得到了对已发表数据的全面审查的支持,但由于儿科数据匮乏、各研究结果相互矛盾或儿科与成人数据存在差异的领域,仍存在未解决的问题。本报告突出了管理中的争议领域,强调了某些专家意见的依据,并通过基于案例的方法提请注意需要进一步研究的主题。

相似文献

1
Debates in Management and Treatment of CMV in Pediatric Solid Organ Transplant Recipients: A Case-Based Discussion.小儿实体器官移植受者巨细胞病毒管理与治疗的辩论:基于病例的讨论
Pediatr Transplant. 2025 Aug;29(5):e70135. doi: 10.1111/petr.70135.
2
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.抗 CMV 病的抗病毒药物用于预防实体器官移植受者。
Cochrane Database Syst Rev. 2024 May 3;5(5):CD003774. doi: 10.1002/14651858.CD003774.pub5.
3
Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients.对巨细胞病毒血症进行抢先治疗以预防实体器官移植受者的巨细胞病毒疾病。
Cochrane Database Syst Rev. 2025 Jan 14;1(1):CD005133. doi: 10.1002/14651858.CD005133.pub4.
4
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.用于预防实体器官移植受者巨细胞病毒病的抗病毒药物。
Cochrane Database Syst Rev. 2013 Feb 28(2):CD003774. doi: 10.1002/14651858.CD003774.pub4.
5
Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients.对巨细胞病毒血症进行抢先治疗以预防实体器官移植受者的巨细胞病毒疾病。
Cochrane Database Syst Rev. 2013 Feb 28;2013(2):CD005133. doi: 10.1002/14651858.CD005133.pub3.
6
WITHDRAWN: Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation.撤回:实体器官移植中使用抗病毒药物进行巨细胞病毒预防。
Cochrane Database Syst Rev. 2007 Jul 18;1998(4):CD001320. doi: 10.1002/14651858.CD001320.pub2.
7
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.用于预防实体器官移植受者巨细胞病毒病的抗病毒药物。
Cochrane Database Syst Rev. 2008 Apr 16(2):CD003774. doi: 10.1002/14651858.CD003774.pub3.
8
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.用于预防实体器官移植受者巨细胞病毒病的抗病毒药物。
Cochrane Database Syst Rev. 2005 Oct 19(4):CD003774. doi: 10.1002/14651858.CD003774.pub2.
9
Patient Number and Treatment Patterns in Cytomegalovirus Viremia and Disease Following Solid Organ and Hematopoietic Stem Cell Transplantation in Germany: Results of a Delphi Consensus Study.德国实体器官和造血干细胞移植后巨细胞病毒血症及疾病的患者数量和治疗模式:德尔菲共识研究结果
Adv Ther. 2025 May 22. doi: 10.1007/s12325-025-03210-x.
10
Synbiotics, prebiotics and probiotics for solid organ transplant recipients.固体器官移植受者的共生元、益生元和益生菌。
Cochrane Database Syst Rev. 2022 Sep 20;9(9):CD014804. doi: 10.1002/14651858.CD014804.pub2.

本文引用的文献

1
The Fourth International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation.《实体器官移植中巨细胞病毒管理的第四届国际共识指南》
Transplantation. 2025 Jul 1;109(7):1066-1110. doi: 10.1097/TP.0000000000005374. Epub 2025 Apr 9.
2
Cytomegalovirus prophylaxis in pediatric liver transplantation: A comparison of strategies across the Society of Pediatric Liver Transplantation (SPLIT) consortium.儿童肝移植中的巨细胞病毒预防:儿科肝移植协会(SPLIT)联盟各策略的比较
Am J Transplant. 2025 May;25(5):1098-1106. doi: 10.1016/j.ajt.2024.09.025. Epub 2024 Oct 3.
3
Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum.
移植相关病毒感染论坛:用于临床试验的移植患者中巨细胞病毒(CMV)感染和疾病(包括耐药和难治性 CMV)的共识定义:2024 年更新。
Clin Infect Dis. 2024 Sep 26;79(3):787-794. doi: 10.1093/cid/ciae321.
4
Multicenter Analysis of Valganciclovir Prophylaxis in Pediatric Solid Organ Transplant Recipients.小儿实体器官移植受者中缬更昔洛韦预防的多中心分析
Open Forum Infect Dis. 2024 Jul 1;11(7):ofae353. doi: 10.1093/ofid/ofae353. eCollection 2024 Jul.
5
Cytomegalovirus detection is associated with ICU admission in non-AIDS and AIDS patients with Pneumocystis jirovecii pneumonia.巨细胞病毒检测与非艾滋病和艾滋病合并肺孢子菌肺炎患者的 ICU 入院相关。
PLoS One. 2024 Jan 10;19(1):e0296758. doi: 10.1371/journal.pone.0296758. eCollection 2024.
6
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.在一项评估马拉韦罗治疗移植受者难治或耐药巨细胞病毒感染的 3 期临床试验中评估耐药性。
J Infect Dis. 2024 Feb 14;229(2):413-421. doi: 10.1093/infdis/jiad293.
7
Body surface area compared to body weight dosing of valganciclovir is associated with increased toxicity in pediatric solid organ transplantation recipients.与体重相比,按体表面积给予缬更昔洛韦会增加儿科实体器官移植受者的毒性。
Am J Transplant. 2023 Dec;23(12):1961-1971. doi: 10.1016/j.ajt.2023.07.013. Epub 2023 Jul 26.
8
Risk factors of cytomegalovirus infection after pediatric liver transplantation and effectiveness of preemptive therapy.小儿肝移植后巨细胞病毒感染的危险因素及预防性治疗的效果。
Transpl Infect Dis. 2023 Jun;25(3):e14057. doi: 10.1111/tid.14057. Epub 2023 Apr 4.
9
Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight-based dosed valganciclovir prophylaxis.儿童肾、肝和心脏移植受者巨细胞病毒血症的发生率:基于体重给药的缬更昔洛韦预防失败的疗效及危险因素
Pediatr Transplant. 2023 Jun;27(4):e14493. doi: 10.1111/petr.14493. Epub 2023 Mar 21.
10
Population pharmacokinetic modeling and simulation of maribavir to support dose selection and regulatory approval in adolescents with posttransplant refractory cytomegalovirus.群体药代动力学建模与模拟玛巴韦尔在移植后难治性巨细胞病毒感染的青少年患者中的应用,支持剂量选择和监管批准。
CPT Pharmacometrics Syst Pharmacol. 2023 May;12(5):719-723. doi: 10.1002/psp4.12943. Epub 2023 Feb 28.